Alkermes to sell Irish manufacturing facility to Novo Nordisk
The facility in Athlone, Ireland, will give Novo Nordisk additional capacity to manufacture oral products.
List view / Grid view
The facility in Athlone, Ireland, will give Novo Nordisk additional capacity to manufacture oral products.
Jessicca Rege of Alkermes provides insights into how protein engineering approaches have led to the development of novel therapies that harness the immune system’s capabilities to fight cancer.
EPR Issue 2 includes articles on the future of cell and gene therapy, the potential of AAV gene therapies, NMR relaxometry and more…
VUMERITY has been granted approved by the FDA for the treatment of relapsing forms of multiple sclerosis based on data from a New Drug Application submission.
7 October 2015 | By Victoria White
Aristada is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection...
9 February 2015 | By Alkermes plc
Alkermes plc announced positive topline results from a phase 1, randomized, double-blind clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule in development for the treatment of multiple sclerosis...
20 December 2011 | By Alkermes
ALKS 9070 is designed to offer once-monthly version of Aripiprazole...
12 September 2011 | By Eli Lilly and Company
Results presented at EASD 2011...
21 June 2011 | By Eli Lilly and Company
Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced that the European Commission has granted marketing authorization to BYDUREON™...
9 May 2011 | By Elan Drug Technologies (EDT)
Alkermes will merge with EDT in a cash and stock transaction currently valued at approximately $960 million...